Matches in SemOpenAlex for { <https://semopenalex.org/work/W2511408899> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2511408899 endingPage "184" @default.
- W2511408899 startingPage "180" @default.
- W2511408899 abstract "Just a few years shy of a century ago, a group of Canadian researchers discovered a viable method of extracting insulin, filling a large and critical gap in the therapeutic treatment of diabetes (1). Since then, insulin and its associated delivery devices have become an integral part of the care and management of patients living with diabetes. Shortly after the first insulin injection was successfully delivered, vials of insulin became available commercially. At this time, large glass syringes were used to administer insulin, and each injection required sterilization of the syringe, as well as sharpening of the syringe needle with a pumice stone. Through the years, insulin syringes modernized, but it was not until the 1970s that an alternate delivery system—the insulin pump, used in continuous subcutaneous insulin infusion (CSII) regimens—became available. Fifteen years later, the first insulin pen was introduced to the marketplace, providing evidence that, as time progresses, there is no shortage of innovation in the diabetes arena.The first two rapid-acting inhaled insulins on the market—Exubera in 2006 and Afrezza in 2014—represented yet another innovation milestone. In theory, inhaled insulin completely eliminated the psychological barriers associated with subcutaneous insulin delivery, such as needle phobia and incorrect injection technique. However, in October 2007, Pfizer withdrew Exubera from the market, and in January 2016, Sanofi withdrew from a $925 million marketing agreement with MannKind for Afrezza; both removals were due to poor sales volume. Although patients and providers have been searching for years for alternatives to injecting insulin, Exubera has already failed, and Afrezza’s destiny is uncertain.In 2006, Exubera was the first inhaled insulin approved by the U.S. Food and Drug Administration (FDA). It showed noninferiority in efficacy with regard to A1C lowering in both type 1 diabetes (2) and type 2 diabetes (3) compared to mixed regular/NPH …" @default.
- W2511408899 created "2016-09-16" @default.
- W2511408899 creator A5012880470 @default.
- W2511408899 creator A5052956709 @default.
- W2511408899 creator A5065659476 @default.
- W2511408899 date "2016-08-01" @default.
- W2511408899 modified "2023-10-17" @default.
- W2511408899 title "Commentary: Why Was Inhaled Insulin a Failure in the Market?" @default.
- W2511408899 cites W1505255102 @default.
- W2511408899 cites W1760782438 @default.
- W2511408899 cites W1973360240 @default.
- W2511408899 cites W1979378398 @default.
- W2511408899 cites W1982984639 @default.
- W2511408899 cites W1987424028 @default.
- W2511408899 cites W2001831366 @default.
- W2511408899 cites W2010233974 @default.
- W2511408899 cites W2017222422 @default.
- W2511408899 cites W2040414998 @default.
- W2511408899 cites W2089590169 @default.
- W2511408899 cites W2094743589 @default.
- W2511408899 cites W2138077952 @default.
- W2511408899 cites W2138533265 @default.
- W2511408899 cites W2158671989 @default.
- W2511408899 cites W2343028046 @default.
- W2511408899 cites W2769264260 @default.
- W2511408899 cites W4380784975 @default.
- W2511408899 doi "https://doi.org/10.2337/diaspect.29.3.180" @default.
- W2511408899 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5001220" @default.
- W2511408899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27574374" @default.
- W2511408899 hasPublicationYear "2016" @default.
- W2511408899 type Work @default.
- W2511408899 sameAs 2511408899 @default.
- W2511408899 citedByCount "50" @default.
- W2511408899 countsByYear W25114088992017 @default.
- W2511408899 countsByYear W25114088992018 @default.
- W2511408899 countsByYear W25114088992019 @default.
- W2511408899 countsByYear W25114088992020 @default.
- W2511408899 countsByYear W25114088992021 @default.
- W2511408899 countsByYear W25114088992022 @default.
- W2511408899 countsByYear W25114088992023 @default.
- W2511408899 crossrefType "journal-article" @default.
- W2511408899 hasAuthorship W2511408899A5012880470 @default.
- W2511408899 hasAuthorship W2511408899A5052956709 @default.
- W2511408899 hasAuthorship W2511408899A5065659476 @default.
- W2511408899 hasBestOaLocation W25114088991 @default.
- W2511408899 hasConcept C126322002 @default.
- W2511408899 hasConcept C177713679 @default.
- W2511408899 hasConcept C2779306644 @default.
- W2511408899 hasConcept C71924100 @default.
- W2511408899 hasConceptScore W2511408899C126322002 @default.
- W2511408899 hasConceptScore W2511408899C177713679 @default.
- W2511408899 hasConceptScore W2511408899C2779306644 @default.
- W2511408899 hasConceptScore W2511408899C71924100 @default.
- W2511408899 hasIssue "3" @default.
- W2511408899 hasLocation W25114088991 @default.
- W2511408899 hasLocation W25114088992 @default.
- W2511408899 hasLocation W25114088993 @default.
- W2511408899 hasLocation W25114088994 @default.
- W2511408899 hasOpenAccess W2511408899 @default.
- W2511408899 hasPrimaryLocation W25114088991 @default.
- W2511408899 hasRelatedWork W1506200166 @default.
- W2511408899 hasRelatedWork W1995515455 @default.
- W2511408899 hasRelatedWork W2048182022 @default.
- W2511408899 hasRelatedWork W2080531066 @default.
- W2511408899 hasRelatedWork W2604872355 @default.
- W2511408899 hasRelatedWork W2748952813 @default.
- W2511408899 hasRelatedWork W2899084033 @default.
- W2511408899 hasRelatedWork W3031052312 @default.
- W2511408899 hasRelatedWork W3032375762 @default.
- W2511408899 hasRelatedWork W3108674512 @default.
- W2511408899 hasVolume "29" @default.
- W2511408899 isParatext "false" @default.
- W2511408899 isRetracted "false" @default.
- W2511408899 magId "2511408899" @default.
- W2511408899 workType "article" @default.